Short Interest in AstraZeneca PLC (OTCMKTS:AZNCF) Declines By 10.0%

AstraZeneca PLC (OTCMKTS:AZNCF) was the target of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 37,100 shares, a decrease of 10.0% from the September 30th total of 41,200 shares. Based on an average daily volume of 2,100 shares, the short-interest ratio is currently 17.7 days.

AstraZeneca Stock Down 0.1 %

Shares of AstraZeneca stock opened at $149.50 on Thursday. AstraZeneca has a 52 week low of $118.16 and a 52 week high of $175.00. The business’s fifty day simple moving average is $158.28 and its 200-day simple moving average is $156.08.

Hedge Funds Weigh In On AstraZeneca

An institutional investor recently bought a new position in AstraZeneca stock. Eagle Bay Advisors LLC acquired a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,001 shares of the company’s stock, valued at approximately $156,000. Institutional investors own 40.87% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.